The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Lyell Immunopharma Inc (NASDAQ: LYEL) was $8.94 for the day, down -1.97% from the previous closing price of $9.12. In other words, the price has decreased by -$1.97 from its previous closing price. On the day, 1.3 million shares were traded. LYEL stock price reached its highest trading level at $9.35 during the session, while it also had its lowest trading level at $8.485.
Ratios:
Our analysis of LYEL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.49 and its Current Ratio is at 7.49. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on October 30, 2024, Downgraded its rating to Underperform and sets its target price to $1 from $6 previously.
On June 27, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $1.
JP Morgan Downgraded its Overweight to Neutral on August 28, 2023, whereas the target price for the stock was revised from $15 to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 31 ’25 when BRAWLEY OTIS W bought 35,640 shares for $0.56 per share. The transaction valued at 19,958 led to the insider holds 35,640 shares of the business.
Ramachandra Sumant bought 200,000 shares of LYEL for $115,220 on Mar 21 ’25. The Director now owns 200,000 shares after completing the transaction at $0.58 per share. On Mar 14 ’25, another insider, Klausner Richard, who serves as the Director of the company, bought 158,000 shares for $0.60 each. As a result, the insider paid 94,942 and bolstered with 843,365 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 132384408 and an Enterprise Value of -112072112. For the stock, the TTM Price-to-Sale (P/S) ratio is 1891.14 while its Price-to-Book (P/B) ratio in mrq is 0.39. Its current Enterprise Value per Revenue stands at -1724.186 whereas that against EBITDA is 0.556.
Stock Price History:
The Beta on a monthly basis for LYEL is -0.24, which has changed by -0.7170886 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, LYEL has reached a high of $38.40, while it has fallen to a 52-week low of $7.65. The 50-Day Moving Average of the stock is -2.09%, while the 200-Day Moving Average is calculated to be -39.75%.
Shares Statistics:
LYEL traded an average of 108.20K shares per day over the past three months and 236170 shares per day over the past ten days. A total of 14.76M shares are outstanding, with a floating share count of 6.40M. Insiders hold about 56.76% of the company’s shares, while institutions hold 21.52% stake in the company. Shares short for LYEL as of 1749772800 were 355342 with a Short Ratio of 3.28, compared to 1747267200 on 485360. Therefore, it implies a Short% of Shares Outstanding of 355342 and a Short% of Float of 3.1600002000000003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
